What is Saama?
Founded in 1997 and headquartered in Campbell, California, Saama Technologies is a prominent player in the clinical data and analytics space. The company leverages an AI-driven platform designed to integrate, curate, and animate diverse data sources, including structured, unstructured, and real-world data. This sophisticated approach enables Saama to deliver critical insights across all therapeutic areas, supporting pharmaceutical companies and research organizations in their efforts to accelerate drug development and improve patient outcomes. Saama's technology is pivotal in transforming complex clinical trial data into actionable intelligence.
How much funding has Saama raised?
Saama has raised a total of $507M across 4 funding rounds:
Series A
$35M
Private Equity
$40M
Debt
$2M
Other Financing Round
$430M
Series A (2015): $35M with participation from Carrick Capital Partners
Private Equity (2019): $40M led by Perceptive Advisors
Debt (2020): $2M supported by PPP
Other Financing Round (2021): $430M featuring Merck Global Health Innovation Fund, Northpond Ventures, and Amgen Business Development
Key Investors in Saama
Merck Global Health Innovation Fund
Merck Global Health Innovation Fund is a growth investor focused on innovative digital health and data science companies, aiming to optimize biopharmaceutical operations and improve patient care.
Perceptive Advisors
Perceptive Advisors is an investment firm specializing in funding innovative healthcare and life sciences technologies, managing significant assets to support groundbreaking advancements.
Amgen Business Development
Amgen Oncology is dedicated to transforming cancer treatment through innovative therapies and a commitment to patient care, focusing on delivering high-quality biosimilar medicines and improving cancer outcomes.
What's next for Saama?
With the recent influx of major strategic investment, Saama Technologies is poised for accelerated growth and enhanced market penetration. The company's focus on AI-driven clinical data analytics positions it at the forefront of digital transformation within the life sciences industry. Future developments are likely to involve expanding its platform capabilities, forging new strategic partnerships, and further integrating real-world evidence into clinical research workflows. This capital infusion will support Saama's mission to streamline clinical development and deliver faster, more effective treatments to patients.
See full Saama company page
